(Q38877415)

7 September 2017

Induction of HIV-specific functional immune responses by a multiclade HIV-1 DNA vaccine candidate in healthy Ugandans (English)

1 reference

7 September 2017

0 references

12

Fred Wabwire-Mangen

0 references

Deborah L. Birx

series ordinal

14

object named as

Deborah L Birx

1 reference

7 September 2017

9

Merlin L Robb

1 reference

7 September 2017

10

Nelson L Michael

1 reference

7 September 2017

16

Josephine H Cox

1 reference

7 September 2017

13

Barney S Graham

1 reference

7 September 2017

1

Michael A Eller

1 reference

7 September 2017

3

Marc S Opollo

1 reference

7 September 2017

11

Hannah Kibuuka

1 reference

7 September 2017

2

Leigh Anne Eller

1 reference

7 September 2017

4

Benson J Ouma

1 reference

7 September 2017

5

Peter O Oballah

1 reference

7 September 2017

8

Silvia Ratto Kim

1 reference

7 September 2017

Lynee Galley

6

1 reference

7 September 2017

Chitraporn Karnasuta

series ordinal

7

1 reference

7 September 2017

Mark S de Souza

series ordinal

15

1 reference

7 September 2017

language of work or name

English

0 references

publication date

17 September 2007

1 reference

7 September 2017

6

1 reference

based on heuristic

inferred from page(s)

published in

Vaccine

1 reference

7 September 2017

25

1 reference

7 September 2017

45

1 reference

7 September 2017

7737-7742

1 reference

Genetic diversity of HIV in Africa: impact on diagnosis, treatment, vaccine development and trials

7 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.056

Among 46 near full length HIV type 1 genome sequences from Rakai District, Uganda, subtype D and AD recombinants predominate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.056

HIV-1 diversity and vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.056

Vaccination of seronegative volunteers with a human immunodeficiency virus type 1 env/rev DNA vaccine induces antigen-specific proliferation and lymphocyte production of beta-chemokines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.056

Excellent safety and tolerability of the human immunodeficiency virus type 1 pGA2/JS2 plasmid DNA priming vector vaccine in HIV type 1 uninfected adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.056

New hope for an AIDS vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.056

A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.056

Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.056

Safety and immunogenicity of an HIV subtype B and E prime-boost vaccine combination in HIV-negative Thai adults.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.056

Antibody-dependent cell-mediated cytotoxic responses in participants enrolled in a phase I/II ALVAC-HIV/AIDSVAX B/E prime-boost HIV-1 vaccine trial in Thailand

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.056

Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.056

Immunogenicity of a recombinant human immunodeficiency virus (HIV)-canarypox vaccine in HIV-seronegative Ugandan volunteers: results of the HIV Network for Prevention Trials 007 Vaccine Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.056

Evaluation of aldrithiol-2-inactivated preparations of HIV type 1 subtypes A, B, and D as reagents to monitor T cell responses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.056

Clinical trials of HIV vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.056

Poxvirus-based vaccine candidates for HIV: two decades of experience with special emphasis on canarypox vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.056

10.1016/J.VACCINE.2007.08.056

7 January 2021

Identifiers

DOI

1 reference

7 September 2017

1 reference